Progression to impaired glucose regulation and diabetes in the population-based Inter99 study

Susanne Engberg, Dorte Vistisen, Cathrine Lau, Charlotte Glümer, Torben Jørgensen, Oluf Pedersen, Knut Borch-Johnsen, Susanne Engberg, Dorte Vistisen, Cathrine Lau, Charlotte Glümer, Torben Jørgensen, Oluf Pedersen, Knut Borch-Johnsen

Abstract

Objective: The purpose of this study was to estimate the progression rates to impaired glucose regulation (impaired fasting glucose or impaired glucose tolerance) and diabetes in the Danish population-based Inter99 study and in a high-risk subpopulation, separately.

Research design and methods: From a population-based primary prevention study, the Inter99 study, 4,615 individuals without diabetes at baseline and with relevant follow-up data were divided into a low- and a high-risk group based on a risk estimate of ischemic heart disease or the presence of risk factors (smoking, hypertension, hypercholesterolemia, obesity, or impaired glucose tolerance). High-risk individuals (57.1%) were examined with an oral glucose tolerance test at 1 and 3 years, and all of the participants were reexamined at the 5-year follow-up. Person-years at risk were calculated. Progression rates to impaired glucose regulation and diabetes were estimated directly from baseline to the 5-year follow-up for all the participants and from baseline through the 1- and 3- to 5-year follow-up examinations for the high-risk individuals, separately.

Results: In the combined low- and high-risk group, 2.1 individuals per 100 person-years progressed from normal glucose tolerance (NGT) to impaired glucose regulation or diabetes. Among high-risk individuals, 5.8 per 100 person-years with NGT progressed to impaired glucose regulation or diabetes, and 4.9 per 100 person-years progressed from impaired glucose regulation to diabetes.

Conclusions: Progression rates to impaired glucose regulation using the current World Health Organization classification criteria were calculated for the first time in a large European population-based study. The progression rates to diabetes show the same pattern as seen in the few similar European studies.

Trial registration: ClinicalTrials.gov NCT00289237.

References

    1. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46: 701– 710, 1997
    1. Schranz AG: Abnormal glucose tolerance in the Maltese: a population-based longitudinal study of the natural history of NIDDM and IGT in Malta. Diabetes Res Clin Pract 7: 7– 16, 1989
    1. Skarfors ET, Selinus KI, Lithell HO: Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 303: 755– 760, 1991
    1. Njølstad I, Arnesen E, Lund-Larsen PG: Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark study. Am J Epidemiol 147: 49– 58, 1998
    1. Qiao Q, Lindström J, Valle TT, Tuomilehto J: Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med 20: 1027– 1033, 2003
    1. Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG: Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 310: 560– 564, 1995
    1. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M: Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 53: 1782– 1789, 2004
    1. Nichols GA, Hillier TA, Brown JB: Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 30: 228– 233, 2007
    1. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999
    1. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285: 2109– 2113, 2001
    1. Valdés S, Botas P, Delgado E, Alvarez F, Cadórniga FD: Population-based incidence of type 2 diabetes in northern Spain: the Asturias Study. Diabetes Care 30: 2258– 2263, 2007
    1. Hanley AJ, Williams K, Gonzalez C, D'Agostino RB, Wagenknecht LE, Stern MP, Haffner SM: San Antonio Heart Study, Mexico City Diabetes Study, Insulin Resistance Atherosclerosis Study: Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 52: 463– 469, 2003
    1. Forouhi NG, Luan J, Hennings S, Wareham NJ: Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. Diabet Med 24: 200– 207, 2007
    1. Magliano DJ, Barr ELM, Zimmet PZ, Cameron AJ, Dunstan DW, Colagiuri S, Jolley D, Owen N, Phillips P, Tapp RJ, Welborn TA, Shaw JE: Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 31: 267– 272, 2008
    1. Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29: 1130– 1139, 2006
    1. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23: 1108– 1112, 2000
    1. Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glümer C, Pisinger C: A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10: 377– 386, 2003
    1. Glümer C, Jørgensen T, Borch-Johnsen K: Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26: 2335– 2340, 2003
    1. Armitage P, Berry G, Matthews J: Statistical Methods in Medical Research. Blackwell Publishing, London, 2002
    1. Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K: National Diabetes Register: The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51: 2187– 2196, 2008
    1. Rasmussen SS, Glümer C, Sandbaek A, Lauritzen T, Borch-Johnsen K: Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark. Diabetologia 50: 293– 297, 2007
    1. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Aunola S, Cepaitis Z, Moltchanov V, Hakumaki M, Mannelin M, Martikkala V, Sundvall J, Uusitupa M: Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343– 1350, 2001
    1. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med 159: 1450– 1456, 1999
    1. Söderberg S, Zimmet P, Tuomilehto J, de-Courten M, Dowse GK, Chitson P, Stenlund H, Gareeboo H, Alberti KG, Shaw J: High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med 256: 37– 47, 2004

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera